Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Buflomedil is a non-selective antagonist of α-adrenergic receptors (α-ARs) and vasoactive compound.1,2,3,4 It binds to rat α1A- and α1B-ARs (Kis = 4.06 and 6.84 µM, respectively) and human platelet α2-ARs (IC50 = 1 µM) in radioligand binding assays.1,2 Buflomedil (0.06-60 µM) inhibits contraction of isolated canine saphenous veins induced by phenylephrine, clonidine (Item No. 15949), sympathetic nerve stimulation, or norepinephrine.3 It inhibits ADP-, collagen-, or epinephrine-induced aggregation of isolated human platelets when used at a concentration of 100 µM.2 Buflomedil (10 mg/kg) reduces hippocampal neuronal cell death in a rat model of carotid clamping-induced ischemia-reperfusion injury.4
WARNING This product is not for human or veterinary use.
1. Inhibitory effect of buflomedil on prostate α1A adrenoceptor in the Wistar rat. Neurosci. Lett. 367(2), 224-227 (2004).
2. In vitro studies of the effect of buflomedil on platelet responsiveness. Haemostasis 20(3), 181-191 (1990).
3. Buflomedil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in peripheral and cerebral vascular diseases. Drugs 33(5), 430-460 (1987).
4. Protective effect of buflomedil in a rat model of moderate cerebral ischemia. Arzneimittelforschung. 55(8), 437-442 (2005).